Conferences - Results from #10040

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate in metastatic castration-resistant prostate cancer, by Oscar B. Goodman Jr., MD, PhD, et al. - Poster February 21, 2013

GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study, by Abdenour Nabid, MD, et al. - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Session Highlights February 20, 2013

GU Cancers Symposium 2013 - Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) February 20, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Podcast February 20, 2013

GU Cancers Symposium 2013 - Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer, by Matthew R. Cooperberg, MD, MPH, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - Open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer patients previously treated with sipuleucel-T: Evaluation of androgen-presenting cell activation, by L. Michael Glode, MD, et al. February 20, 2013

GU Cancers Symposium 2013 - Utilization of cancer detection by U.S. prostate biospies (2005-2011), by Carl A. Olsson, MD, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - Radical or partial nephrectomy for localized disease in elderly patients? by Alexander Kutikov, MD - Session Highlights February 20, 2013

GU Cancers Symposium 2013 - Radical or partial nephrectomy for localized disease in elderly patients? by John L. Gore, MD, MS - Session Highlights February 20, 2013

GU Cancers Symposium 2013 - The ERα agonist, GTx-758, decreases bone turnover markers in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

GU Cancers Symposium 2013 - Advanced prostate cancer patients treated with GTx-758 have a significantly lower rate of hot flashes, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD - Session Highlights February 19, 2013

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation February 19, 2013

GU Cancers Symposium 2013 - GTx-758, an ERα agonist, reduces serum free testosterone and serum PSA in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer: Immune results, by Emmanuel S. Antonarakis, MD, et al February 19, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Sipuleucel-T delayed time to first use of opioid analgesics in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in the IMPACT trial, by Eric J. Small, MD, et al. - Poster February 19, 2013

Page 503 of 525